Avanços na quimioterapia do câncer ginecológico: uma revisão/ Advances in gynecological cancer chemotherapy: a review

João Alberto Lins de Lima, Francisco Henrique da Silva, Izaulinda Marques da Rocha Campelo, Brenda da Silva Oliveira, Salatiel Henrique Pereira de Lima, Aline Cláudia Almeida de Britto da Silva, Arnon de Melo Andrade Júnior, Elyda Gonçalves de Lima

Abstract


Este trabalho teve por objetivo fazer uma análise integrativa da Literatura acerca de como anda o panorama da quimioterapia dos diversos cânceres do trato ginecológico, através de um levantamento rebuscado de artigos que tratem sobre substâncias de origem vegetal, animal, mineral ou sintética que podem ser utilizadas na terapia do câncer ginecológico de modo que seus mecanismos sejam mais seletivos que os fármacos utilizados na clínica., bem como os novos tratamentos que estão em desenvolvimento. Para isso, foram avaliados artigos no período de 2017 à 2020 acerca dessa temática. A metodologia consistiu de uma análise integrativa quanto aos principais relatos da Literatura referentes ao tratamento e as principais características do câncer ginecológico. Como resultados, observou-se que a existência de novas substâncias para o tratamento do câncer ginecológico é bastante estudada, possuindo resultados promissores e com resultados aprovados ou testes clínicos próximos da aprovação pelo FDA.


Keywords


Perspectivas terapêuticas, Quimioterapia, Tratamento.

References


AAPRO, M. S. et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Annals of Oncology, v. 14, n. 3, p. 441-448, 2003.

AGHAJANIAN, Carol et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Journal of clinical oncology, v. 29, n. 16, p. 2259, 2011.

AGGARWAL, M. et al. Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth. Cell death and differentiation, v. 23, n. 10, p. 1615, 2016.

AKRAM, Tahira; MASEELALL, Priya; FANNING, James. Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. American journal of obstetrics and gynecology, v. 192, n. 5, p. 1365-1367, 2005.

ALBERTS, David S. Carboplatin versus cisplatin in ovarian cancer. In: Seminars in oncology. 1995. p. 88-90.

ARAGONA, Alejandro M. et al. Tailoring the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva: Neoadjuvant Chemotherapy Followed by Radical SurgeryResults From a Multicenter Study. International Journal of Gynecological Cancer, v. 22, n. 7, p. 1258-1263, 2012.

ARMSTRONG, Deborah K. et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New England Journal of Medicine, v. 354, n. 1, p. 34-43, 2006.

ASANO, Hiroshi; TODO, Yukiharu; WATARI, Hidemichi. Adjuvant chemotherapy for early-stage cervical cancer. Chinese Journal of Cancer Research, v. 28, n. 2, p. 228, 2016.

BEAVER, Julia A. et al. FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor–positive, HER2-negative metastatic breast cancer. Clinical Cancer Research, v. 21, n. 21, p. 4760-4766, 2015.

BELLATI, Filippo et al. Single agent cisplatin chemotherapy in surgically resected vulvar cancer patients with multiple inguinal lymph node metastases. Gynecologic oncology, v. 96, n. 1, p. 227-231, 2005.

BENEDETTI-PANICI, Pierluigi et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of clinical oncology, v. 20, p. 179-188, 2002.

Benedetti-Panici P, Greggi S, Scambia G, Salerno G, Mancuso S. Cisplatin (P), bleomycin (B), and methotrexate (M) preoperative chemotherapy in locally advanced vulvar carcinoma. Gynecol Oncol 1993; v. 50, p. 49–53

BEREK, Jonathan S. et al. Concurrent cisplatin and 5-fluorouracil chemotherapy and radiation therapy for advanced-stage squamous carcinoma of the vulva. Gynecologic oncology, v. 42, n. 3, p. 197-201, 1991.

BERGAMINI, A. et al. Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin. Gynecologic oncology, v. 144, n. 1, p. 72-76, 2017.

BHEEMANAPALLY, Khaggeswar et al. In vitro anti-cancer activity of rosuvastatin and ketorolac nanoformulations against DDX3. Journal of Young Pharmacists, v. 9, n. 4, p. 537, 2017.

BOL, G. M. et al. Targeting DDX3 with a small molecule inhibitor for lung câncer therapy. EMBO molecular medicine, v. 7, n. 5, p. 648-669, 2015.

BURGER, Robert A. et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. Journal of clinical oncology, v. 25, n. 33, p. 5165-5171, 2007.

BURGER, Robert A. et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. New England Journal of Medicine, v. 365, n. 26, p. 2473-2483, 2011.

BURKE, Thomas W. et al. Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. Gynecologic oncology, v. 51, n. 3, p. 397-400, 1993.

CORMIO, Gennaro et al. Cisplatin and vinorelbine chemotherapy in recurrent vulvar carcinoma. Oncology, v. 77, n. 5, p. 281-284, 2009.

CHEN, Jen-Ruei et al. Salvage chemotherapy in recurrent cervical cancer with biweekly pegylated liposomal doxorubicin (lipo-dox). Taiwanese Journal of Obstetrics and Gynecology, v. 47, n. 3, p. 322-326, 2008.

CRONIN, Beth et al. Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer: Is There a Role for Maintenance Therapy?. Clinical Ovarian and Other Gynecologic Cancer, v. 6, n. 1-2, p. 17-20, 2013.

CUNNINGHAM, Mary J. et al. Primary radiation, cisplatin, and 5-fluorouracil for advanced squamous carcinoma of the vulva. Gynecologic oncology, v. 66, n. 2, p. 258-261, 1997.

CRISTOFANILLI, Massimo et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. The Lancet Oncology, v. 17, n. 4, p. 425-439, 2016.

DAWOOD, Rehana; INSTONE, Margaret; KEHOE, Sean. Neo-adjuvant chemotherapy for cervical cancer in pregnancy: a case report and literature review. European Journal of Obstetrics & Gynecology and Reproductive Biology, v. 171, n. 2, p. 205-208, 2013.

DEPPE, Gunter et al. Chemotherapy of vulvar cancer: a reviewChemotherapie des Karzinoms der Vulva. Wiener klinische Wochenschrift, v. 125, n. 5-6, p. 119-128, 2013.

DU BOIS, Andreas et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute, v. 95, n. 17, p. 1320-1329, 2003.

DU BOIS, A. et al. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: A prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecologic oncology, v. 107, n. 3, p. 518-525, 2007.

DUENAS-GONZALEZ, A. et al. A phase II study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation. Annals of oncology, v. 14, n. 8, p. 1278-1284, 2003.

DUNTON, Charles J. et al. Treatment of advanced and recurrent endometrial cancer with cisplatin, doxorubicin, and cyclophosphamide. Gynecologic oncology, v. 41, n. 2, p. 113-116, 1991.

EISENHAUER, Elizabeth A. et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. Journal of Clinical Oncology, v. 12, n. 12, p. 2654-2666, 1994.

FERRANDINA, Gabriella et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. Journal of Clinical Oncology, v. 26, n. 6, p. 890-896, 2008.

FLEMING, Gini F. et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. Journal of Clinical Oncology, v. 22, n. 11, p. 2159-2166, 2004.

FORNER, Dirk Michael; MALLMANN, Peter. Neoadjuvant and definitive chemotherapy or chemoradiation for stage III and IV vulvar cancer: A pooled Reanalysis. European Journal of Obstetrics & Gynecology and Reproductive Biology, v. 212, p. 115-118, 2017.

FUJIMURA, Hidehiko et al. Adjuvant chemotherapy including cisplatin in endometrial carcinoma. Gynecologic and obstetric investigation, v. 50, n. 2, p. 127-132, 2000.

GARUFI, A. et al. Reactivation of mutant p53 by capsaicin, th major constituent of peppers. Journal od Experimental & Clinical Cancer Research, v. 35, p. 136, 2016.

GALAAL, Khadra et al. Adjuvant chemotherapy for advanced endometrial cancer. Cochrane Database of Systematic Reviews, n. 5, 2014.

GEISLER, John P.; MANAHAN, Kelly J.; BULLER, Richard E. Neoadjuvant chemotherapy in vulvar cancer: avoiding primary exenteration. Gynecologic oncology, v. 100, n. 1, p. 53-57, 2006.

GHAEMMAGHAMI, F.; BEHTASH, N.; YARANDI, F.; MOOSAVI, U. M.; MODARES, H.; TOOGEH, L.; KHANAFSHAR, N. Quimioterapia de primeira linha com 5-FU e platina para câncer avançado e recorrente do colo do útero: um estudo de fase II. J. Obstet. Gyneacol. v. 23, n. 4, p. 422-425, 2003.

GORDON, Alan N. et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecologic oncology, v. 95, n. 1, p. 1-8, 2004.

GREEN, John A. et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. The Lancet, v. 358, n. 9284, p. 781-786, 2001.

GRIGSBY, P. W. Cancer vaginal. Current Treatment Options in Oncology, v. 3, p. 125-130, 2002.

GUO, R. et al. Discovered of ERBB3 inhibitors for non-small cell lung cancer (NSCLC) via virtual scrennig. J. Mol. Model, v. 22, p. 135, 2016.

GUPTA, A. et al. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment. Biomedicine & Pharmacotherapy, v. 109, p. 484-492, 2019.

GUO, R. et al. Discovered of ERBB3 inhibitors for non-small cell lung cancer (NSCLC) via virtual scrennig. J. Mol. Model, v. 22, p. 135, 2016.

GUPTA, A. et al. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment. Biomedicine & Pharmacotherapy, v. 109, p. 484-492, 2019.

HAN, Sileny N.; VERGOTE, Ignace; AMANT, Frédéric. Weekly paclitaxel/carboplatin in the treatment of locally advanced, recurrent, or metastatic vulvar cancer. International Journal of Gynecological Cancer, v. 22, n. 5, p. 865-868, 2012.

HELM, C. William et al. Enhancing the efficacy of cisplatin in ovarian cancer treatment–could arsenic have a role. Journal of ovarian research, v. 2, n. 1, p. 2, 2009.

HEUDEL, P. E. et al. Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group. British journal of cancer, v. 116, n. 3, p. 303, 2017.

HOFFMAN, Mitchel S. et al. Treatment of recurrent and metastatic cervical cancer with cis-platin, doxorubicin, and cyclophosphamide. Gynecologic oncology, v. 29, n. 1, p. 32-36, 1988.

HÖGBERG, Thomas; GLIMELIUS, Bengt; NYGREN, Peter. A systematic overview of chemotherapy effects in ovarian cancer. Acta oncologica, v. 40, n. 2-3, p. 340-360, 2001.

HOGBERG, Thomas et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer–results from two randomised studies. European journal of cancer, v. 46, n. 13, p. 2422-2431, 2010.

HOMESLEY, Howard D. et al. Phase II trial of liposomal doxorubicin at 40 mg/m2 every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecologic oncology, v. 98, n. 2, p. 294-298, 2005.

IWATA, Takashi et al. Neoadjuvant chemotherapy for locally advanced cervical cancer. Chinese Journal of Cancer Research, v. 28, n. 2, p. 235, 2016.

JURADO, M. et al. Pilot study of concurrent cisplatin, 5-fluorouracil, and external beam radiotherapy prior to radical surgery+/− intraoperative electron beam radiotherapy in locally advanced cervical cancer. Gynecologic oncology, v. 74, n. 1, p. 30-37, 1999.

JURIC, Dejan et al. Phosphatidylinositol 3-kinase α-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study. Journal of Clinical Oncology, v. 36, n. 13, p. 1291-1299, 2018.

KALAGHCHI, Bita et al. Concurrent chemoradiation with weekly paclitaxel and cisplatin for locally advanced cervical cancer. Asian Pac J Cancer Prev, v. 17, n. 5, p. 82-88, 2016.

KEHOE, Sean et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. The Lancet, v. 386, n. 9990, p. 249-257, 2015.

KIDD, E. A. et al. Comparison of Outcomes for Cervical Cancer Patients Treated With Radiation and Concurrent Weekly Cisplatin Versus Cisplatin and 5-Fluorouracil. International Journal of Radiation Oncology• Biology• Physics, v. 90, n. 1, p. S475, 2014.

KITAGAWA, Ryo et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. Journal of Clinical Oncology, v. 33, n. 19, p. 2129-2135, 2015.

LANDINI, Ida et al. Selection and characterization of a human ovarian cancer cell line resistant to auranofin. Oncotarget, v. 8, n. 56, p. 96062, 2017.

LIU, J. F. et al. Randomized phase II trial of seribantumab in combination with paclitaxel in patients with advanced platinum-resistant or refractory ovarian cancer. Journal of Clinical Oncology. v. 34, p. 4345-4353, 2016.

LIU, Huidi et al. Main components of pomegranate, ellagic acid and luteolin, inhibit metastasis of ovarian cancer by down-regulating MMP2 and MMP9. Cancer biology & therapy, v. 18, n. 12, p. 990-999, 2017.

LIU, Qing et al. Luteolin promotes the sensitivity of cisplatin in ovarian cancer by decreasing PRPA1-medicated autophagy. Cellular and molecular biology (Noisy-le-Grand, France), v. 64, n. 6, p. 17-22, 2018.

LITTON, Jennifer K. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine, v. 379, n. 8, p. 753-763, 2018.

LONG, H. J. et al. Phase II Evaluation of Carboplatin in Advanced Endometrial Carcinoma1. JNCI: Journal of the National Cancer Institute, v. 80, n. 4, p. 276-278, 1988.

LONG, Harry J. et al. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina. Gynecologic oncology, v. 57, n. 2, p. 235-239, 1995.

LORVIDHAYA, Vicharn et al. Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial. International Journal of Radiation Oncology* Biology* Physics, v. 55, n. 5, p. 1226-1232, 2003.

LORUSSO, Domenica et al. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecologic oncology, v. 133, n. 1, p. 117-123, 2014.

LOVE, Richard R. et al. Side effects and emotional distress during cancer chemotherapy. Cancer, v. 63, n. 3, p. 604-612, 1989.

LUPI, Giovanni et al. Combined preoperative chemoradiotherapy followed by radical surgery in locally advanced vulvar carcinoma: a pilot study. Cancer: Interdisciplinary International Journal of the American Cancer Society, v. 77, n. 8, p. 1472-1478, 1996.

MABUCHI, Seiji et al. The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy. Gynecologic oncology, v. 113, n. 2, p. 200-204, 2009.

MACCAURO, Giulio et al. Physiopathology of spine metastasis. International journal of surgical oncology, v. 2011, 2011.

MAK, Raymond H. et al. Outcomes after radiation therapy with concurrent weekly platinum-based chemotherapy or every-3–4-week 5-fluorouracil-containing regimens for squamous cell carcinoma of the vulva. Gynecologic oncology, v. 120, n. 1, p. 101-107, 2011.

MAKKER, Vicky et al. A multicenter, single‐arm, open‐label, phase 2 study of apitolisib (GDC‐0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). Cancer, v. 122, n. 22, p. 3519-3528, 2016.

MARKHAM, Anthony. Copanlisib: first global approval. Drugs, v. 77, n. 18, p. 2057-2062, 2017.

MATHI, P. et al. In-Vitro and In-Silico characterization of Sophora interrupta plant extract as an anticancer activity. Bioinformation, v. 10, n. 3, p. 144, 2014.

MIYAMOTO, David T.; VISWANATHAN, Akila N. Concurrent chemoradiation for vaginal cancer. PloS one, v. 8, n. 6, p. e65048, 2013.

MICHALAREA, Vasiliki et al. Abstract CT010: Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g) BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations. 2016.

MIŠE, Branka Petric et al. Long follow-up of patients with locally advanced cervical cancer treated with concomitant chemobrachyradiotherapy with cisplatin and ifosfamide followed by consolidation chemotherapy. International Journal of Gynecologic Cancer, v. 25, n. 2, p. 315-319, 2015.

MONK, Bradley J. et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. Journal of Clinical Oncology, v. 27, n. 7, p. 1069, 2009.

MOORE, Kathleen N. et al. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecologic oncology, v. 105, n. 2, p. 299-303, 2007.

MOROTTI, Matteo et al. Bevacizumab in endometrial cancer treatment. Expert opinion on biological therapy, v. 12, n. 5, p. 649-658, 2012.

MORRIS, Mitchell et al. Treatment of small cell carcinoma of the cervix with cisplatin, doxorubicin, and etoposide. Gynecologic oncology, v. 47, n. 1, p. 62-65, 1992.

MOK, Tony S. et al. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. New England Journal of Medicine, v. 376, n. 7, p. 629-640, 2017.

MS / INCA / Coordenação de Prevenção e Vigilância / Divisão de Vigilância e Análise de Situação, 2020

MUDERSPACH, Laila I. et al. Carboplatin as a radiation sensitizer in locally advanced cervical cancer: a pilot study. Gynecologic oncology, v. 65, n. 2, p. 336-342, 1997.

MUGGIA, Franco M. et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. Journal of Clinical Oncology, v. 15, n. 3, p. 987-993, 1997.

MUGGIA, Franco M. et al. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. Journal of clinical oncology, v. 20, n. 9, p. 2360-2364, 2002.

NORONHA, Vanita et al. Metastatic myoepithelial carcinoma of the vulva treated with carboplatin and paclitaxel. The lancet oncology, v. 7, n. 3, p. 270-271, 2006.

OZOLS, Robert F. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer. In: Seminars in oncology. 2000. p. 3-7.

OZOLS, Robert F. et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. Journal of Clinical Oncology, v. 21, n. 17, p. 3194-3200, 2003.

OOMMEN, Deepu; YIANNAKIS, Dennis; JHA, Awadhesh N. BRCA1 deficiency increases the sensitivity of ovarian cancer cells to auranofin. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, v. 784, p. 8-15, 2016.

PARK, SEE-HyOUNg et al. Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53. International journal of oncology, v. 45, n. 4, p. 1691-1698, 2014.

PARK, Dong Choon et al. Phase II trial of neoadjuvant paclitaxel and cisplatin in uterine cervical cancer. Gynecologic oncology, v. 92, n. 1, p. 59-63, 2004.

PECTASIDES, D. et al. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecologic oncology, v. 109, n. 2, p. 250-254, 2008.

PENSON, Richard T. et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology–Gynecologic Oncology Group protocol 240). The Lancet Oncology, v. 16, n. 3, p. 301-311, 2015.

PICCART, Martine J. et al. Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. Journal of the National Cancer Institute, v. 92, n. 9, p. 699-708, 2000.

PUJADE-LAURAINE, Eric et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. Obstetrical & Gynecological Survey, v. 69, n. 7, p. 402-404, 2014.

RAHAMAN, Jamal et al. Chemotherapy for gynecologic cancers. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine: A Journal of Translational and Personalized Medicine, v. 76, n. 6, p. 577-588, 2009.

RAHANGDALE, Lisa et al. Topical 5-fluorouracil for treatment of cervical intraepithelial neoplasia 2: a randomized controlled trial. American journal of obstetrics and gynecology, v. 210, n. 4, p. 314. e1-314. e8, 2014.

RAJA, F. A.; CHOPRA, N.; LEDERMANN, J. A. Optimal first-line treatment in ovarian cancer. annals of Oncology, v. 23, n. suppl_10, p. x118-x127, 2012.

RANDALL, Marcus E. et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. Journal of Clinical Oncology, v. 24, n. 1, p. 36-44, 2006.

REIN, D. T. et al. Weekly carboplatin and docetaxel for locally advanced primary and recurrent cervical cancer: a phase I study. Gynecologic oncology, v. 87, n. 1, p. 98-103, 2002.

RICHARD, S. D. et al. Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab. International Journal of Gynecological Cancer, v. 18, n. 5, p. 1132-1135, 2008.

RITCHIE, Peter. Cause of Death. Black & White Publishing Ltd, 2017.

ROSE, Peter G. et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. New England Journal of Medicine, v. 340, n. 15, p. 1144-1153, 1999.

ROSE, Peter G. et al. Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecologic oncology, v. 102, n. 2, p. 210-213, 2006.

ROSE, Peter G. et al. Paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma. International Journal of Gynecological Cancer, v. 27, n. 3, p. 452-458, 2017.

SAMAL, S. K. et al. Ketorolac salt is a newly discovered DDX3 inhibitor to treat oral cancer. Scientific reports, v. 5, p. 9982, 2015.

SCHOEBERL, B et al. Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121). NPJ systems biology and applications, v. 3, p. 16034.

SCANLON, K. J. et al. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proceedings of the National Academy of Sciences, v. 83, n. 23, p. 8923-8925, 1986.

SHAO, Fang-Yuan et al. EM23, a natural sesquiterpene lactone, targets thioredoxin reductase to activate JNK and cell death pathways in human cervical cancer cells. Oncotarget, v. 7, n. 6, p. 6790, 2016.

SHIH, Ted; LINDLEY, Celeste. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clinical therapeutics, v. 28, n. 11, p. 1779-1802, 2006.

SHIMIZU, Yoshio; HASUMI, Katsuhiko; MASUBUCHI, Kazumasa. Effective chemotherapy consisting of bleomycin, vincristine, mitomycin C, and cisplatin (BOMP) for a patient with inoperable vulvar cancer. Gynecologic oncology, v. 36, n. 3, p. 423-427, 1990.

SIKANDER, Mohammed et al. Cucurbitacin D exhibits potent anti-cancer activity in cervical cancer. Scientific reports, v. 6, p. 36594, 2016.

SISAY, Mekonnen; EDESSA, Dumessa. PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers. Gynecologic oncology research and practice, v. 4, n. 1, p. 18, 2017.

SOVAK, Mika A. et al. Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study. Gynecologic oncology, v. 103, n. 2, p. 451-457, 2006.

SULLIVAN, S. A. et al. SPR965, a PI3K/mTORC1/2 inhibitor, as a targeted therapy in endometrial cancer. Gynecologic Oncology, v. 149, p. 171, 2018.

SUSUMU, Nobuyuki et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate-and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecologic oncology, v. 108, n. 1, p. 226-233, 2008.

TAL, P. et al. Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides. Oncotarget, v. 7, n. 11, p. 11817-11837, 2016.

TAKEMOTO, Shuji et al. Primary adenocarcinoma of the vagina successfully treated with neoadjuvant chemotherapy consisting of paclitaxel and carboplatin. Journal of Obstetrics and Gynaecology Research, v. 35, n. 3, p. 579-583, 2009.

TAURIN, Sebastien et al. Endometrial cancers harboring mutated fibroblast growth factor receptor 2 protein are successfully treated with a new small tyrosine kinase inhibitor in an orthotopic mouse model. International Journal of Gynecological Cancer, v. 28, n. 1, p. 152, 2018.

TEEKARAMAN, D. et al. Quercetin inhibits human metastatic ovarian cancer cell growth by modulating intrinsic apoptotic pathway in PA-1 cell line. Chemico-biological interactions, 2019.

TEWARI, Krishnansu S. et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). The Lancet, v. 390, n. 10103, p. 1654-1663, 2017.

THARAVICHITKUL, Ekkasit et al. Combined chemoradiation of cisplatin versus carboplatin in cervical carcinoma: a single institution experience from Thailand. BMC cancer, v. 16, n. 1, p. 501, 2016.

THOMAS, G. et al. Concurrent radiation and chemotherapy in vulvar carcinoma. Gynecologic oncology, v. 34, n. 3, p. 263-267, 1989.

TINKER, A. V. et al. Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience. Gynecologic oncology, v. 98, n. 1, p. 54-58, 2005.

TIRMAZY, Syed Hammad et al. Chemotherapy for advanced endometrial cancer with carboplatin and epirubicin. Anticancer research, v. 34, n. 7, p. 3793-3798, 2014.

VAN DOORN, H. C. et al. Neoadjuvant chemoradiation for advanced primary vulvar cancer. Cochrane Database Syst Rev, v. 3, n. July 19, p. CD003752, 2006.

VLACHOSTERGIOS, P. J.; PAPANDREOU, C. N. Bevacizumab in advanced cervical cancer. Clinical and Translational Oncology, v. 16, n. 10, p. 935-935, 2014.

WAHL, Daniel R.; LAWRENCE, Theodore S. No sugar added: A new strategy to inhibit glioblastoma receptor tyrosine kinases. Clinical Cancer Research, v. 25, n. 2, p. 455-456, 2019.

WAHNER HENDRICKSON, A. E. et al. 1001TiP A phase II clinical trial of veliparib and topotecan in patients with platinum resistant ovarian cancer. Annals of Oncology, v. 29, n. suppl_8, p. mdy285. 208, 2018.

WAHLEN, Steven A. et al. Concurrent radiation therapy and chemotherapy in the treatment of primary squamous cell carcinoma of the vulva. Cancer, v. 75, n. 9, p. 2289-2294, 1995.

WANG, Shuhang; CANG, Shundong; LIU, Delong. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. Journal of hematology & oncology, v. 9, n. 1, p. 34, 2016.

WANG, Haixia et al. Luteolin sensitizes the antitumor effect of cisplatin in drug-resistant ovarian cancer via induction of apoptosis and inhibition of cell migration and invasion. Journal of ovarian research, v. 11, n. 1, p. 93, 2018.

WELANDER, Charles E.; HOMESLEY, Howard D.; BARRETT, Rolland J. Combined interferon alf a and doxorubicin in the treatment of advanced cervical cancer. American Journal of Obstetrics & Gynecology, v. 165, n. 2, p. 284-291, 1991.

WOODRUFF, J. Donald; PARMLEY, T. H.; JULIAN, C. G. Topical 5-fluorouracil in the treatment of vaginal carcinoma-in-situ. Gynecologic oncology, v. 3, n. 2, p. 124-132, 1975.

WRIGHT, Jason D. et al. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecologic oncology, v. 103, n. 2, p. 489-493, 2006.

YANG, Zongyuan et al. Quercetin induces endoplasmic reticulum stress to enhance cDDP cytotoxicity in ovarian cancer: involvement of STAT3 signaling. The FEBS journal, v. 282, n. 6, p. 1111-1125, 2015.

ZHANG, S. et al. Small molecule NSC59984 restores p53 pathway signaling and anti-tumor effects against colorectal cancer via p73 activation and degradation of mutant p53. Cancer Research, v. 75, n. 18, p. 3842-3852, 2015.

ZIGHELBOIM, Israel et al. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecologic oncology, v. 130, n. 1, p. 64-68, 2013.




DOI: https://doi.org/10.34117/bjdv6n7-102

Refbacks

  • There are currently no refbacks.